Skip to main content

Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P

Publication: Clin Chim Acta (2014) • Vol 430 • Page 86-91PMID: 24412321View on PubMed

Purpose

The purpose of this paper was to determine the effects of patient gender, age, and disease state on levels of soluble human epidermal growth factor receptor 2 (HER2) in serum. In addition, these levels were compared to HER2 in tissue.

Conclusion

Serum from healthy men had higher levels of the extracellular domain (ECD) of HER2 than serum from healthy women. In healthy women and female previous cancer patients, HER2 ECD levels were higher in serum from older women than from younger women, but patient age had no effects on HER2 ECD levels among serum from healthy men. No significant differences were seen in HER2 ECD levels between specimens from current and former breast cancer patients. Regardless of metastases, significantly higher HER2 ECD levels were measured in serum when the corresponding tissue specimens had HER2 immunohistochemistry scores of 3+ rather than 2+, 1+, or 0, but this was only true for the current breast cancer patients who had not undergone treatment, as no correlations were observed between HER2 ECD levels and HER2 immunostaining scores among specimens from previous cancer patients who had been treated.

Studies (1)

Purpose

The purpose of this study was to determine the effects of patient gender, age, and disease state on levels of soluble HER2 ECD in serum. In addition, these levels were compared to HER2 in tissue. Breast tumor tissue and serum from 565 cancer patients were analyzed before any chemotherapy or radiation. In addition, serum from 283 healthy individuals and serum and breast tissue from 249 patients with a history of breast cancer (had previously undergone chemotherapy and radiation and were cancer free) was also included in the study. Serum was stored frozen at -80 degrees C until assay. Breast tissue was fixed in formalin and embedded in paraffin. For specimens with a DAKO score of 2+, FISH was also performed to determine HER2 status.

Summary of Findings

Serum from healthy men had higher levels of HER2 ECD than serum from healthy women (p<0.001). Among healthy women and those with a previous cancer diagnosis, HER2 ECD levels were higher in serum from older women than from younger women (p<0.001 and p=0.03, respectively), but patient age had no effects on HER2 levels among serum from healthy men. HER2 ECD levels were not compared between serum from healthy females and current breast cancer patients since the median ages for these groups were significantly different (37 y and 58 y, respectively). However, no significant differences were seen in HER2 ECD levels between specimens from current and former breast cancer patients. HER2 positivity in tissue was associated with negative estrogen receptor (ER) and progesterone receptor (PR) status, metastases, large tumor size, lymph node involvement, and high-grade tumors. Multivariate analysis revealed a significant correlation between higher levels of HER2 ECD in serum and postmenopausal status and metastases, while lymph node involvement, tumor grading, and ER/PR status did not show significant correlations with HER2 ECD levels. Regardless of metastases, significantly higher HER2 ECD levels were measured in serum when the corresponding tissue specimens had HER2 immunohistochemistry scores of 3+ rather than 2+, 1+, or 0, but this was only true for the current breast cancer patients who had not undergone treatment, as no correlations were observed between HER2 ECD levels and HER2 immunostaining scores among specimens from previous cancer patients who had been treated.

  • Biospecimens

    TissueBreast
    FluidSerum
    FluidBlood
  • Preservation Types

    FrozenFormalin
  • Diagnoses

    Normal
    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    ProteinImmunoassay
    DNAFISH
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionBiomarker level
    Negative ER status
    Negative PR status
    Positive ER status
    Positive PR status
    PreaquisitionDiagnosis/ patient condition
    Current diagnosis of breast cancer
    Normal
    Prior diagnosis of breast cancer (remission)
    PreaquisitionOther drugs
    No prior chemotherapy or radiation
    Prior chemotherapy and radiation
    PreaquisitionPatient age
    35-45 years
    45-55 years
    <35 years
    Older than 55 years
    Postmenopausal
    Premenopausal
    PreaquisitionPatient gender
    Female
    Male
    PreaquisitionPrognostic factor
    Distant metastases
    G1 grade tumor
    G2 grade tumor
    G3 grade tumor
    Large tumor size
    Lymph node involvement
    No distant metastases
    No lymph node involvement
    Small tumor size
    UICC stage I
    UICC stage II
    UICC stage III
    Biospecimen AcquisitionBiospecimen location
    Breast tissue
    Serum